The present disclosure relates generally to medical devices and delivery systems for the same.
The left atrial appendage (LAA) originates from the left wall of the left atrium. This fingerlike projection opens to the atrium through an ovoid orifice and extends 2-4 cm long, pointing towards the apex.
Atrial fibrillation (AF) is the most common arrhythmia (i.e. irregularly timed contraction) and oftentimes occurs due to sustained increased left atrial afterload—leading to an enlargement of the left atrium (LA). The presence of AF may establish a positive feedback loop that furthers enlargement and increases the probability of thrombus (i.e. clotting) formation. As the LAA is not contracting on time, blood stasis occurs in the appendage as the blood flows into the appendage but does not flow out in a rhythmic fashion. This leads to blood clotting in the appendage, which then becomes a risk as the irregular contraction of the LAA may force the clot to travel out of the appendage and into the brain, leading to an ischemic stroke.
It is believed by researchers that up to 90 percent of the clots found in the brain come from the LAA. If AF patients are not treated, their risk of stroke increases as they age; 15 percent of all strokes are caused by AF. However, in patients 70 years and older, more than 20 to 25 percent of strokes are caused by atrial fibrillation.
Current research suggests that occlusion of the left atrial appendage reduces the risk of ischemic stroke in atrial fibrillation patients by preventing LAA thrombus formation from occurring. It also acts as an alternative therapy to oral anticoagulation (OAC). Some patients elect to not take OACs or are ineligible due to side effects.
Delivering a left atrial appendage occlusion device may be challenging due to varying LAA morphologies. Thus, flush deployment of an LAA occlusion device may not easily be achieved. It is in an objective of this invention to provide a flush deployment of a LAA occlusion device through an improved delivery system.
According to various embodiments, the systems and methods herein include an apparatus for delivering a medical device to one or more bodily orifices, the apparatus including: A) a substantially cylindrical core cannula having a proximal end and a distal end; B) a locking member operatively coupled to the distal end of the core cannula; C) one or more expandable members coupled to the distal end of the core cannula, wherein the one or more expandable members are configured for expanding from a compressed position to an expanded position; and D) one or more injection apparatuses inserted into a hollow portion along a length of the core cannula, the one or more injection apparatuses defining at least one opening at a distal end for transmitting fluid.
In one or more embodiments, the systems and methods herein include a medical device delivery system, the delivery system including: A) a substantially cylindrical core cannula having a proximal end and a distal end; B) a locking member operatively coupled to the distal end of the core cannula; C) one or more expandable members coupled to the distal end of the core cannula, wherein the one or more expandable members: i) have a substantially circular cross-section; ii) are compressible from an expanded position to a compressed position; and iii) remain compressed within a hollow access sheath; D) a substantially cylindrical injection apparatus inserted into a hollow portion along a length of the core cannula, the injection apparatus defining at least one opening at a distal end for transmitting fluid; and E) the hollow access sheath, wherein the hollow access sheath surrounds a portion of the length of the core cannula, the locking member, and the one or more expandable members.
In at least one embodiment, the systems and methods herein include a method for delivering an implantable medical device, the method including: A) providing a delivery system detachably connected to an implantable medical device, the delivery system including: i) a substantially cylindrical core cannula having a proximal end and a distal end; ii) a locking member operatively coupled to the distal end of the core cannula; iii) one or more expandable members coupled to the distal end of the core cannula, wherein the one or more expandable members are configured for expanding from a compressed position to an expanded position; and iv) at least one injection apparatus inserted into a hollow portion along a length of the core cannula, the at least one injection apparatus defining at least one opening at a distal end for transmitting fluid; B) threading the delivery system through a hollow access sheath through a patient to an area of implant; C) causing the one or more expandable members to exit the hollow access sheath and thereby expanding to the expanded position; D) injecting fluid into the implantable medical device via the at least one injection apparatus thereby causing the implantable medical device to expand; and E) detaching the implantable medical device from the delivery system.
Further features and benefits of the present disclosure will be apparent from a detailed description of various embodiments thereof taken in conjunction with the following drawings, wherein similar elements are referred to with similar reference numbers, and wherein:
Whether or not a term is capitalized is not considered definitive or limiting of the meaning of a term. As used in this document, a capitalized term shall have the same meaning as an uncapitalized term, unless the context of the usage specifically indicates that a more restrictive meaning for the capitalized term is intended. However, the capitalization or lack thereof within the remainder of this document is not intended to be necessarily limiting unless the context clearly indicates that such limitation is intended.
For the purpose of promoting an understanding of the principles of the present disclosure, reference will now be made to the embodiments illustrated in the figures and specific language will be used to describe the same. It will, nevertheless, be understood that no limitation of the scope of the disclosure is thereby intended; any alterations and further modifications of the described or illustrated embodiments, and any further applications of the principles of the disclosure as illustrated therein are contemplated as would normally occur to one skilled in the art to which the disclosure relates. All limitations of scope should be determined in accordance with and as expressed in the claims.
This application is related to and incorporates by reference herein the following U.S. and international patent applications:
U.S. Provisional Patent Appln. No. 61/984,342, entitled “LEFT ATRIAL APPENDAGE OCCLUSION DEVICE”, filed on Apr. 25, 2014; and
PCT Appln. No. PCT/US15/27666, entitled “LEFT ATRIAL APPENDAGE OCCLUSION DEVICE”, filed on Apr. 24, 2015.
The above references are incorporated by reference herein. Any incorporation by reference is not intended to give a definitive or limiting meaning of a particular term. In the case of a conflict of terms, this document governs.
The present systems and methods relate to a system of delivering an implantable, inflatable device comprising of soft polymeric material(s) with a one-way sealing system and insertable fluid for inflation while keeping the device flush to the surrounding tissue. In various embodiments, the present systems and methods relate to a system of delivering an implantable, inflatable device for occupying body cavities, e.g. the left atrial appendage, etc.
Exemplary delivery devices such as those disclosed herein may provide several advantages over previous delivery systems, including giving a user of the exemplary delivery device an ability to deploy an implant device inside a body cavity flush with nearby tissue walls by one or more expandable members attached to the delivery system, deployed through, in some embodiments, a standard transeptal procedure providing a secure and slender attachment to an implant device.
Turning now to the figures, in the embodiment shown in
In various embodiments, the exemplary core cannula 32 is constructed from polymeric materials, including polyurethane, latex, Pebax, nylon, PET or silicone. According to particular embodiments, the core cannula 32 is hollow, thin-walled, and contains a central smaller hole at the proximal end for an injection apparatus or multiple injection apparatuses (e.g., injection apparatus 34) to pass through. In particular embodiments, the outer diameter of the core cannula 32 will allow the transport of an implantable device within (e.g., 8 Fr (2.666 mm), 10 Fr (3.333 mm), 12 Fr (4 mm), etc.). In at least one embodiment, the length of the core cannula is enough to reach from an access point on a patient to the delivery destination, such as the patient's LAA (e.g., usable length of 75 cm, 85 cm, 95 cm. etc.).
In one or more embodiments, the hollow injection apparatus 34 allows for fluid to pass through to inflate a device that may be attached to the device locking member 36. The injection apparatus 34 may be formed of metallic materials, shape memory materials, fiber reinforced materials, and/or polymer materials. In various embodiments, there are one or more injection apparatus containing one or more holes or various shapes (e.g., circular, ovular, etc.) and sizes (e.g., 0.25 mm, 0.5 mm, 0.75 mm, etc.) per apparatus along the exterior distal length. In particular embodiments, the distal end of the one or more injection apparatuses are rounded or blunt to reduce the risk of puncturing tissue or a compliant attached device. In at least one embodiment, the outer diameter of the injection apparatus 34 will allow the transport of fluid (e.g. contrast, sterile water, saline, hydrogels, or non-viscous to semi-viscous fluids) to an implantable device (e.g., 1 mm, 1.5 mm, 2 mm, etc.). The length of the injection apparatus is enough to reach from a user end of a delivery system (
In at least one embodiment, the device locking member 36, which may be constructed out of metal materials (e.g., aluminum, nitinol, stainless steel, etc.) or polymeric material(s) (e.g., silicone, polyurethane, etc.), is located at the distal end of the core cannula 32 and allows for attachment/detachment of a connected device (as further discussed herein). The device locking member 36 may be attached to the core cannula 32 through a fastening method (e.g., adhesives, screws, welding, etc.) and/or may be at least partially or fully integrally formed with the core cannula 32. The device locking member 36 may operate as a twist lock method or luer lock method such that the device could untwist from a helical thread or unlock from an indentation within the device locking member 36. In the embodiment shown in
Turning now to
The expanding members 38 may be configured to expand under a number of suitable conditions and/or via a number of suitable mechanisms. According to particular embodiments, the expanding members 38 expand once exposed inside the body and will compressed upon being retrieved through an access sheath (e.g., the expanding members are compressed at a first diameter by the diameter of the access sheath and expand upon exiting the access sheath to a predetermined second diameter. In various embodiments, the expanding members 38 expand through a method (e.g., trigger, sensor, feedback system etc.) on the user end of an exemplary delivery system as shown in
Turning now to
In particular embodiments, the injection apparatus handle 46 is located at the proximal end of an injection apparatus 34 for maneuvering the length of the injection apparatus 34 and any injection fluids that may be passed through the injection apparatus 34. In particular embodiments, the delivery system may include multiple injection apparatuses 34. In these embodiments, there may be one or more injection apparatus handles 46 attached to one or more corresponding injection apparatus 34 through adhesives, welding, and/or molding techniques.
In at least one embodiment, the delivery catheter member 42 travels through the hollow access sheath 40 and is attached to the core cannula 32, the device deployment handle 44, or body of the core cannula 32 through methods such as adhesives, welding, or molding techniques. In particular embodiments, the device deployment handle 44 controls the detachment of an implantable device operatively connected to the distal end of the core cannula 32 (not shown in
The exemplary delivery system shown in
Delivering a left atrial appendage closure (LAAC) for a particular patient is briefly described, as shown in
In particular embodiments, imaging techniques, such as transesophageal echocardiography (TEE), will be performed to measure the LAA to determine device size. The procedure is then performed under appropriate imaging, which may include fluoroscopic, intracardiac echocardiographic (ICE), or TEE guidance. A transseptal needle attached to a guidewire (not shown) will then puncture the intraatrial septum, allowing for the transseptal access sheath 40 to advance over the transseptal needle and through the puncture within the intraatrial septum into the left atrium. The transseptal needle and the guidewire are then removed from the system. An adhesive or locking mechanism (not shown) will be attached to the transseptal access sheath 40 to prevent movement of the sheath 40. The transseptal access sheath 40 contains a hemostasis valve 48 to prevent backflow of bodily fluid. A delivery catheter embodiment 42 is then advanced through the access sheath 40 to aid in directing the implantable device. A core cannula 32 with a proximal or user and distal or device end can then be advanced through the access sheath 40, where the distal end of the core cannula 32 includes a portion to aid in eventual placement of the implantable device. The core cannula 32 is directed through the body to the targeted body cavity, for example, the left atrial appendage, under fluoroscopic, ICE, or TEE guidance. Once the distal portion of the core cannula 32 exits the access sheath 40, expandable members 38 attached to the distal portion of the core cannula 32 will move from a first position (within the access sheath) to a second, expanded position to allow the implant device to expand in a position inside a body cavity, while keeping the device flush or in the same plane with nearby tissue.
As discussed herein, the expandable members 38 can be constructed as a wire from a self-expanding, super elastic element, such as Nitinol, etc. and can be coated or enclosed by chemical or physical means, such as a polymeric, elastomeric material, etc. to prevent harm towards neighboring bodily structures. In one embodiment, once the expandable members 38 have exited the access sheath 40, the expandable members 38 will expand to a pre-determined shape, such as a round, ovular, cross, diamond, spring etc. formation. The expandable members 38 along with the core cannula 32 are advanced towards the opening of the body cavity until the expandable members 38 reach the opening and engage with the surrounding tissue, preventing the core cannula 32 from advancing further. The expanding members 38 may be constructed to take into account varying sizes of the body cavity and can be sized incrementally (e.g., gradient of 1 mm, 1.5 mm, 2 mm, etc.) in the form of a spring basket (e.g., as shown in
According to particular embodiments, once the expandable members 38, core cannula 32, and implantable device are in place, an injection apparatus 34 with a proximal and distal end is inserted through the core cannula 32 and travels to the body cavity (as will be understood by one of ordinary skill in the art, an injection apparatus 34, in various embodiments, may be pre-inserted in the core cannula 32 and the implantable device). In various embodiments, the proximal end of an injection apparatus 34 includes an injection apparatus handle 46 to manipulate the length and position of an injection apparatus 34 as well as to reduce the risk of advancing an injection apparatus 34 through the entirety of the body cavity during the pre-insertion period. In particular embodiments, the distal end of the core cannula 32 is pre-attached to the implantable device through the device locking member 36, which may include a twisting system, luer lock system, etc. In one or more embodiments, the distal end of an injection apparatus 34 is pre-inserted or moved inside the implantable device to allow for fluid ejection. In particular embodiments, a fluid is injected into an injection apparatus 34 through a syringe (not shown) until the device has successfully occluded the body cavity (as discussed in applications incorporated by reference herein). In at least one embodiment, upon assessment of successful occlusion through imaging and final contrast injections, an injection apparatus 34 is removed, and the core cannula is detached from the implantable device via the device locking member 36 via a twisting method, at the device deployment handle 44 found on the proximal end of the core cannula 32. In one embodiment, the device deployment handle 44 further includes one or more injection apparatus handles 46 that are operatively connected to an injection apparatus 34. In particular embodiments, the distal end of the core cannula 32 detaches from the implantable device and is removed from the patient along with the access sheath 40. Following the retrieval of the core cannula 32, attached expandable members 38 are compressed into the access sheath 40.
In a first alternate embodiment, an exemplary device may include expandable members of varying locations on the delivery system. In this first alternate embodiment, a shape memory structure (such as nitinol or PEEK) can be attached at a proximal end, a distal end, or other locations along the length of the exemplary delivery device. Continuing with this embodiment, the length of the shape memory structure may range from a portion to the entire length of the delivery system. In this alternate embodiment, the shape memory material may be fabricated through braiding, laser cutting, or wiring to allow for differentiating morphologies. As will be understood by one of ordinary skill in the art, heat treatments may also be applied to the shape memory material to yield independent shapes.
Various embodiments of the device herein are depicted as multiple cannulae with eggbeater-shaped expandable members, but the expandable members may be in suitable alternate shapes, including cylindrical, ovular, cross-shaped, multiangular, or coil-shaped. Further, in particular embodiments, the expandable members may be attached to each other with adhesives or shape memory material. In some embodiments, the expansion of the expanding members could be mechanically manipulated through attached wiring, threading, or a balloon that can expand via user control.
As shown in
In particular embodiments, the delivery system may have multiple steering stages, wherein each stage can move in multiple planes. The steering stages may integrate multiple shape memory wires that are heat treated to independently control the wire configurations and the consequent steering stages. The steering capability can be controlled by methods (e.g., trigger, switch, etc.) found on the user end of an exemplary delivery system. This delivery system with multiple steering stages could be implemented for various scenarios, including delivering implantable technologies, angioplasty, valve repair, and drug therapy. In alternate embodiments, the point of attachment between the delivery system and device can vary. Attachment systems include luer-lock systems, anti-rotation systems, microscrew mechanisms. In other embodiments, the location of the attached device to the delivery system may vary, including being within the expanding members or located proximally or distally in relation to the expanding members. In further alternate embodiments, the delivery system may not be detachable from a connected device. In scenarios, such as angioplasty, a balloon or attached device may be attached to the delivery system through adhesives, molding, or welding.
In various embodiments, the distal end of the delivery system may contain a sensor unit. In such embodiments, the sensor unit's purpose may include but not limited to detection of thrombus, physiological function, sterility, or microbial activity.
In some embodiments, a coating may be applied to the delivery system. The purpose of the coating may include but not limited to lubricity, microbial stability, fluid absorption, and encrustation reduction. In alternate embodiments, the material of the delivery system may be induced with elements, such as tungsten or silver, to increase levels of radiopacity, microbial stability, allergy reduction, durability, or sterility.
In particular embodiments, the various tube-like components (e.g., core cannula, access sheath, etc.) of the delivery system may be mechanically or chemically enhanced to increase flexibility or durability. In a particular embodiment, a coil could be integrated within the core cannula through molding or welding techniques for increased functionality. Continuing with this embodiment, the tightness or pitch of the wound coil along the length of the core cannula may vary. In an alternative embodiment, the coil could also be braided.
In some embodiments, more than one injection apparatus may be inserted into the delivery system. This may be applicable in scenarios requiring delivery of multiple injectable fluids or fluids that require at least a two-part mixture. Examples of such injectable materials include hydrogels, occlusion gels, etc.
In various embodiments, the device attached to the delivery system may be a balloon. In alternate embodiments, a device with expandable members (e.g. nitinol) may be delivered through the delivery system. Alternatively, in particular embodiments, a device with woven fiber (e.g. PET, ePTFE, Dacron) may be deployed through the delivery system.
The delivery system may be used for identification of general soft tissue concavities or areas in need of occlusion. In various embodiments, the expandable elements of the delivery system allow for precise deployment of an attached device. In some embodiments, these characteristics may be appropriate for closure of atrial septal defects (ASDs) and patent foramen ovales (PFOs), which are defects found in the atrial septal wall. Alternatively, the core cannula elements along with the functionality of the delivery system could be used for drug delivery to a blood vessel during angioplasty. In particular embodiments, the delivery system may be intended for balloon valvuloplasty to mechanically force the opening of a narrowed heart valve. In further embodiments, a drug eluting element may be added to reduce further calcification.
Accordingly, the reader will see that the aforementioned delivery system can be used to easily deploy an implantable, expandable device into a body cavity, such as a LAA, easy-to-use system to deploy the device, and allows the device to be flush against the surrounding tissue.
While the above description contains many specificities, these should not be construed as limitations on the scope of any embodiment, but as exemplifications of various embodiments thereof. Many other ramifications and variations are possible within the teachings of the various embodiments. For example, the attachment embodiments may differ compared to the drawings, the delivery system may alter in shape, size, and multiple similar devices could be used for other applications, etc.
Thus the scope should be determined by the appended claims and their legal equivalents, and not by the examples given.
This application is a national stage application of and claims the benefit of and priority under 35 U.S.C. § 371 to International Patent Application No. PCT/US2015/050967, filed Sep. 18, 2015, entitled “LEFT ATRIAL APPENDAGE OCCLUSION DEVICE DELIVERY SYSTEM,” and under 35 U.S.C. §§ 119, 120 to U.S. Provisional Patent No. 62/052,480, filed Sep. 19, 2014, entitled “LEFT ATRIAL APPENDAGE OCCLUSION DEVICE DELIVERY SYSTEM,” each of which are incorporated herein by reference in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2015/050967 | 9/18/2015 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2016/044740 | 3/24/2016 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4545367 | Tucci | Oct 1985 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4917089 | Sideris | Apr 1990 | A |
5433727 | Sideris | Jul 1995 | A |
5634936 | Linden et al. | Jun 1997 | A |
5792179 | Sideris | Aug 1998 | A |
6019778 | Wilson et al. | Jan 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6238416 | Sideris | May 2001 | B1 |
6293960 | Ken | Sep 2001 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6579303 | Amplatz | Jun 2003 | B2 |
6652556 | VanTassel et al. | Nov 2003 | B1 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6981980 | Sampson et al. | Jan 2006 | B2 |
6994092 | Van Der Burg et al. | Feb 2006 | B2 |
7128073 | Van Der Burg et al. | Oct 2006 | B1 |
7152605 | Khairkhahan et al. | Dec 2006 | B2 |
7284488 | Maruyama et al. | Oct 2007 | B2 |
7318829 | Kaplan et al. | Jan 2008 | B2 |
7537012 | Mohanraj | May 2009 | B2 |
7566336 | Corcoran et al. | Jul 2009 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7665466 | Figulla et al. | Feb 2010 | B2 |
7842069 | Widomski et al. | Nov 2010 | B2 |
7955354 | Figulla et al. | Jun 2011 | B2 |
8080032 | Van Der Burg et al. | Dec 2011 | B2 |
8097015 | Devellian | Jan 2012 | B2 |
8100938 | Figulla et al. | Jan 2012 | B2 |
8152758 | Chan et al. | Apr 2012 | B2 |
8221445 | Van Tassel et al. | Jul 2012 | B2 |
8523897 | Van Der Burg et al. | Sep 2013 | B2 |
8535343 | Van Der Burg et al. | Sep 2013 | B2 |
8545530 | Eskridge et al. | Oct 2013 | B2 |
8562643 | Tekulve et al. | Oct 2013 | B2 |
8597324 | Briganti et al. | Dec 2013 | B2 |
8636732 | Davis et al. | Jan 2014 | B2 |
8636764 | Miles et al. | Jan 2014 | B2 |
8647361 | Borillo et al. | Feb 2014 | B2 |
8663245 | Francischelli et al. | Mar 2014 | B2 |
8663268 | Quinn et al. | Mar 2014 | B2 |
8663273 | Khairkhahan et al. | Mar 2014 | B2 |
8685055 | Van Tassel et al. | Apr 2014 | B2 |
8690910 | Carley et al. | Apr 2014 | B2 |
8690911 | Miles et al. | Apr 2014 | B2 |
8715302 | Ibrahim et al. | May 2014 | B2 |
8715318 | Miles et al. | May 2014 | B2 |
8721663 | Kaplan et al. | May 2014 | B2 |
8740934 | McGuckin, Jr. | Jun 2014 | B2 |
8747452 | Fischell et al. | Jun 2014 | B2 |
8747454 | Khairkhahan et al. | Jun 2014 | B2 |
8753303 | Weisman et al. | Jun 2014 | B2 |
8764765 | Piskun et al. | Jul 2014 | B2 |
8764793 | Lee | Jul 2014 | B2 |
8814931 | Wang et al. | Aug 2014 | B2 |
9770234 | Sideris et al. | Sep 2017 | B2 |
10076335 | Zaver et al. | Sep 2018 | B2 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030149463 | Solymar et al. | Aug 2003 | A1 |
20040254594 | Alfaro | Dec 2004 | A1 |
20050004652 | van der Burg | Jan 2005 | A1 |
20050033331 | Burnett et al. | Feb 2005 | A1 |
20050070957 | Das | Mar 2005 | A1 |
20050113861 | Corcoran et al. | May 2005 | A1 |
20050177182 | Van Der Burg et al. | Aug 2005 | A1 |
20050216052 | Mazzocchi et al. | Sep 2005 | A1 |
20050234543 | Glaser et al. | Oct 2005 | A1 |
20060020278 | Burnett et al. | Jan 2006 | A1 |
20060020327 | Lashinski | Jan 2006 | A1 |
20060265043 | Mandrusov et al. | Nov 2006 | A1 |
20070083224 | Hively | Apr 2007 | A1 |
20070083230 | Javois | Apr 2007 | A1 |
20070129753 | Quinn et al. | Jun 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070179345 | Santilli | Aug 2007 | A1 |
20080033457 | Francischelli et al. | Feb 2008 | A1 |
20080215031 | Belfort | Sep 2008 | A1 |
20090099596 | McGuckin, Jr. et al. | Apr 2009 | A1 |
20090149879 | Dillon | Jun 2009 | A1 |
20090171428 | Hansen | Jul 2009 | A1 |
20090209999 | Afremov | Aug 2009 | A1 |
20100185233 | Thommen | Jul 2010 | A1 |
20110022079 | Miles et al. | Jan 2011 | A1 |
20110077622 | Weisman | Mar 2011 | A1 |
20110178539 | Holmes, Jr. et al. | Jul 2011 | A1 |
20110288558 | Nimgaard | Nov 2011 | A1 |
20120116269 | McAuley | May 2012 | A1 |
20120191125 | Babkes et al. | Jul 2012 | A1 |
20120271343 | Borillo et al. | Oct 2012 | A1 |
20120283585 | Werneth et al. | Nov 2012 | A1 |
20120283773 | Van Tassel et al. | Nov 2012 | A1 |
20120289776 | Keast et al. | Nov 2012 | A1 |
20130018413 | Oral et al. | Jan 2013 | A1 |
20130116724 | Clark et al. | May 2013 | A1 |
20130138138 | Clark et al. | May 2013 | A1 |
20130190799 | Clark | Jul 2013 | A1 |
20130218192 | Erzberger et al. | Aug 2013 | A1 |
20130218193 | Erzberger et al. | Aug 2013 | A1 |
20130237908 | Clark | Sep 2013 | A1 |
20130331884 | Van Der Burg et al. | Dec 2013 | A1 |
20130338696 | Sideris | Dec 2013 | A1 |
20140039536 | Cully et al. | Feb 2014 | A1 |
20140058371 | Krishnan | Feb 2014 | A1 |
20140074151 | Tischler et al. | Mar 2014 | A1 |
20140100596 | Rudman et al. | Apr 2014 | A1 |
20140107696 | Borillo et al. | Apr 2014 | A1 |
20140114340 | Zhou et al. | Apr 2014 | A1 |
20140163605 | Van Tassel et al. | Jun 2014 | A1 |
20140188157 | Clark | Jul 2014 | A1 |
20150151826 | Geneste | Jun 2015 | A1 |
20160100843 | Sideris | Apr 2016 | A1 |
20160192912 | Kassab et al. | Jul 2016 | A1 |
20170143318 | Hu | May 2017 | A1 |
20180338767 | Dasnurkar et al. | Nov 2018 | A1 |
20180360432 | Corcoran et al. | Dec 2018 | A1 |
20180368820 | Rad et al. | Dec 2018 | A1 |
20180368855 | Edmiston et al. | Dec 2018 | A1 |
20180368856 | Miles et al. | Dec 2018 | A1 |
20180369594 | Werneth et al. | Dec 2018 | A1 |
20190000604 | Eli | Jan 2019 | A1 |
20190008495 | Li | Jan 2019 | A1 |
20190008626 | Janardhan et al. | Jan 2019 | A1 |
20190009057 | Li et al. | Jan 2019 | A1 |
20190015109 | Li | Jan 2019 | A1 |
20190021711 | Li | Jan 2019 | A1 |
20190021741 | Chen et al. | Jan 2019 | A1 |
20190038294 | Tieu et al. | Feb 2019 | A1 |
20190038316 | Gillespie et al. | Feb 2019 | A1 |
20190046170 | Coyle et al. | Feb 2019 | A1 |
20190046210 | Bowman | Feb 2019 | A1 |
20190046213 | Gong et al. | Feb 2019 | A1 |
20190053810 | Griffin | Feb 2019 | A1 |
20190069901 | Forbes | Mar 2019 | A1 |
20190071800 | Koppe | Mar 2019 | A1 |
20190076136 | Zhang et al. | Mar 2019 | A1 |
20190083075 | Onushko et al. | Mar 2019 | A1 |
20190088368 | Grodzki et al. | Mar 2019 | A1 |
20190090841 | Degertekin et al. | Mar 2019 | A1 |
20190090884 | Bowman | Mar 2019 | A1 |
20190090885 | Zhou et al. | Mar 2019 | A1 |
20190090945 | Whayne et al. | Mar 2019 | A1 |
20190090951 | Camus et al. | Mar 2019 | A1 |
20190099062 | Ishihara et al. | Apr 2019 | A1 |
20190110796 | Jayaraman | Apr 2019 | A1 |
20190110880 | Fox et al. | Apr 2019 | A1 |
20190117204 | Wang et al. | Apr 2019 | A1 |
20190117229 | Ibrahim et al. | Apr 2019 | A1 |
20190117260 | Ahmad | Apr 2019 | A1 |
20190117300 | Whayne et al. | Apr 2019 | A1 |
20190125302 | Clark | May 2019 | A1 |
20190125350 | Fung et al. | May 2019 | A1 |
20190125362 | Tischler | May 2019 | A1 |
20190125375 | Palushi et al. | May 2019 | A1 |
20190125400 | Ibrahim et al. | May 2019 | A1 |
20190125439 | Rohl et al. | May 2019 | A1 |
20190125513 | Purcell et al. | May 2019 | A1 |
20190125938 | Chen et al. | May 2019 | A1 |
20190133528 | Kassab et al. | May 2019 | A1 |
20190133563 | Glimsdale | May 2019 | A1 |
20190133744 | Janardhan et al. | May 2019 | A1 |
20190133745 | Janardhan et al. | May 2019 | A1 |
20190133746 | Janardhan et al. | May 2019 | A1 |
20190142300 | Friedman et al. | May 2019 | A1 |
20190142428 | Widenhouse et al. | May 2019 | A1 |
20190142431 | Liu et al. | May 2019 | A1 |
20190142434 | Miller | May 2019 | A1 |
20190142567 | Janardhan et al. | May 2019 | A1 |
20190142568 | Janardhan et al. | May 2019 | A1 |
20190150932 | Cruise et al. | May 2019 | A1 |
20190150937 | Kassab | May 2019 | A1 |
Number | Date | Country |
---|---|---|
2007130724 | Nov 2007 | WO |
2013068466 | May 2013 | WO |
2013192332 | Dec 2013 | WO |
Entry |
---|
International Search Report and Written Opinion dated Dec. 17, 2015 in related International Patent Application PCT/US2015/050967. |
European Search Report and Written Opinion dated Nov. 16, 2017 for European Patent Application No. 15783150.4. |
European Search Report and Written Opinion dated Sep. 3, 2018 for European Patent Application No. 15842602.3. |
International Search Report and Written Opinion dated Jul. 28, 2015 for related International Patent Application PCT/US2015/027666. |
“Transcatheter Patch.” Custom Medical Devices. Custom Medical Devices, n.d. Web. Jul. 29, 2014. http://www.custommedicaldevices.net/products/transcatheter-patch/. |
Number | Date | Country | |
---|---|---|---|
20170290594 A1 | Oct 2017 | US |
Number | Date | Country | |
---|---|---|---|
62052480 | Sep 2014 | US |